Use of PYLARIFY® in Specific Patient Groups

Web Exclusives —November 23, 2021
Neal D. Shore, MD
Carolina Urologic Research Center, Myrtle Beach, SC
Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent.
Related Articles
Impact of Age on Efficacy and Safety of Relugolix: A Subgroup Analysis from the Randomized, Phase 3 HERO Study versus Leuprolide in Men with Advanced Prostate Cancer
Michael S. Cookson, MD, MMHC, Neal D. Shore, MD, Daniel J. George, MD, Hideyuki Akaza, MD, Daniel R. Saltzstein, MD, Ronald Tutrone, MD, Alberto Bossi, MD, Bruce Brown, MD, Bryan Selby, MS, Sophia Lu, PhD, Jackie Walling, MBChB, PhD, Bertrand Tombal, MD, PhD, Fred Saad, MD
December 2021 Vol 12, No 12
PYLARIFY Imaging in High-Risk Prostate Cancer
Web Exclusives
Dr Steven Rowe expands on the sensitivity and specificity of PYLARIFY® (piflufolastat F 18) imaging in high-risk prostate cancer.
Practical Applications and Clinical Utility of PYLARIFY® (piflufolastat F 18) Injection: An ¹⁸F-PSMA PET/CT Imaging Agent for Prostate Cancer
Interview with the Innovators – December 2021
A series of interviews was recently conducted with a panel of experts on prostate cancer imaging modalities that included Steven Rowe, MD, PhD, Associate Professor of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, and Neal D. Shore, MD, FACS, CMO, Surgical Oncology/Urology Genesis Care, US; Director, CPI, Carolina Urologic Research Center, Myrtle Beach, SC.
Last modified: November 23, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State
  • Please enter your mailing address.

    Address Line 2
    Zip Code